Our pioneering platform is being developed to combine functional nanocarriers with blood brain barrier traversing ligands for application with a range of therapeutics including small molecules, biologicals and nucleic acids. Architecturally designed from natural biocompatible materials, BioCyto aims to revolutionise the field of neurological medicine.
Neuromedicine Delivery Challenges
Delivery of therapeutics to the brain is notoriously challenging due to the natural protective properties of the blood-brain-barrier resulting in poor efficacy and toxicity complications. Brain targeted drug delivery systems require particularly complex transport means in a benign manner that are not currently available.
Mode of Action
Together with our partners, BioCyto has combined a polymer nanocarrier with a blood brain barrier traversing ligand which is chemically bonded to the chemotherapeutic, methotrexate. Using an in vitro BBB model system in which endothelial cells derived from human induced pluripotent stem cells were co-cultured with an astrocyte cell line, BioCyto has demonstrated a 4 to 5-fold increase in transport across the BBB, in comparison to BSA nanoparticle controls. No nanoparticle-induced toxicity was observed in the endothelial cells.